Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Simple item page
dc.contributor.authorYıldırım H.Ç.
dc.contributor.authorMutlu E.
dc.contributor.authorChalabiyev E.
dc.contributor.authorÖzen M.
dc.contributor.authorKeskinkılıç M.
dc.contributor.authorÖn S.
dc.contributor.authorÇelebi A.
dc.contributor.authorDursun B.
dc.contributor.authorAcar Ö.
dc.contributor.authorKahraman S.
dc.contributor.authorAykan M.B.
dc.contributor.authorKaman Ö.
dc.contributor.authorDoğan A.
dc.contributor.authorErdoğan A.P.
dc.contributor.authorMelisa Celayir Ö.
dc.contributor.authorGünenç D.
dc.contributor.authorGüven D.C.
dc.contributor.authorVedat Bayoğlu İ.
dc.contributor.authorYavuzşen T.
dc.contributor.authorHacıbekiroğlu İ.
dc.contributor.authorİnanç M.
dc.contributor.authorKılıçkap S.
dc.contributor.authorYalçın Ş.
dc.contributor.authorAksoy S.
dc.date.accessioned2024-07-22T08:03:47Z
dc.date.available2024-07-22T08:03:47Z
dc.date.issued2022
dc.description.abstractBackground: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) male breast cancer. Therefore; we aimed to investigate the treatment responses of metastatic HR+, HER2-male breast cancer patients treated with CDK 4–6 inhibitors in a multicenter real-life cohort. Methods: Male patients with a diagnosis of HR+ and HER2-metastatic breast cancer, treated with any CDK 4–6 inhibitor, were included in the study. Demographic and clinical characteristics of the patients were recorded. We aimed to determine progression-free survival (PFS) time, response rates and drug related side effects. Results: A total 25 patients from 14 institutions were recruited. The mean age at diagnosis was 57 years. Median follow-up was 19.53 (95% CI: 14.04–25.02) months. The overall response rate was 60%. While the median PFS was 20.6 months in the whole cohort, it wasn't reached in those using CDK 4–6 inhibitors in first line and 10 months in the subsequent lines (p:0.009). No new adverse events were encountered. Conclusion: In our study, we found that CDK 4–6 inhibitors are effective and safe options in men with HR+ and HER2-metastatic breast cancer as in women. Our results support the use of CDK 4–6 inhibitor-based combinations in the first-line treatment of HR+ and HER2-metastatic male breast cancer. © 2022
dc.identifier.DOI-ID10.1016/j.breast.2022.09.009
dc.identifier.issn09609776
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/12440
dc.language.isoEnglish
dc.publisherChurchill Livingstone
dc.rightsAll Open Access; Green Open Access
dc.subjectAminopyridines
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectBreast Neoplasms
dc.subjectBreast Neoplasms, Male
dc.subjectCyclin-Dependent Kinase 4
dc.subjectCyclin-Dependent Kinase 6
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectProtein Kinase Inhibitors
dc.subjectReceptor, ErbB-2
dc.subjectalanine aminotransferase
dc.subjectaromatase inhibitor
dc.subjectcyclin dependent kinase 4
dc.subjectcyclin dependent kinase 6
dc.subjectcyclin dependent kinase inhibitor
dc.subjectfulvestrant
dc.subjectgonadorelin
dc.subjectpalbociclib
dc.subjectribociclib
dc.subjectaminopyridine derivative
dc.subjectantineoplastic agent
dc.subjectcyclin dependent kinase 4
dc.subjectcyclin dependent kinase 6
dc.subjectepidermal growth factor receptor 2
dc.subjectprotein kinase inhibitor
dc.subjectadult
dc.subjectanemia
dc.subjectArticle
dc.subjectasthenia
dc.subjectcancer combination chemotherapy
dc.subjectcancer diagnosis
dc.subjectcancer patient
dc.subjectcancer survival
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectclinical outcome
dc.subjectcohort analysis
dc.subjectdemographics
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug use
dc.subjectfollow up
dc.subjecthormone receptor positive breast cancer
dc.subjecthuman
dc.subjecthuman epidermal growth factor receptor 2 negative breast cancer
dc.subjectmale
dc.subjectmale breast cancer
dc.subjectmetastatic breast cancer
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectneutropenia
dc.subjectoverall response rate
dc.subjectprogression free survival
dc.subjectQT interval
dc.subjectside effect
dc.subjectsurvival time
dc.subjectthrombocytopenia
dc.subjecttreatment response
dc.subjectbreast tumor
dc.subjectclinical trial
dc.subjectfemale
dc.subjectmetabolism
dc.subjectpathology
dc.titleClinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
dc.typeArticle

Files

Collections

Scopus Koleksiyonu